Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News from Gene Therapy

2 'Strong Buy'-Rated Stocks That Could Rally 39% to 48% in 2025

Both of these growth stocks are positioned for long-term success.

Barchart

NHS to offer ‘life-changing’ gene therapy for blood disorder thalassaemia

Treatment may be offered to hundreds with severe form of disease, most often found in people of Mediterranean, Asian and Middle Eastern heritage

The Guardian - UK

Goldman Sachs Expects Market Sentiment To Support Smaller Firms, Sees Upside of up to 165% for Two Biotech Stocks

Goldman Sachs analysts believe small- and equal-weight benchmarks will keep outperforming unless Q2 reports of big tech companies lead analysts to bump their sales forecasts for the latter half of this year and 2025.

International Business Times UK

From analysis to the latest developments in health,
read the most diverse news in one place.

Why Lexeo Therapeutics Collapsed 26%, Sacrificing A Breakout In Bearish Fashion

Lexeo Therapeutics stock crashed Monday despite promising results for a gene therapy designed to treat heart problems of a genetic condition.

Investors Business Daily

Takeaways from AP's report on access to gene therapies for rare diseases

The promise of gene therapy looms large for families dealing with rare, genetic disorders

The Independent UK

Gene therapy may cure rare diseases. But drugmakers have few incentives, leaving families desperate

The promise of gene therapy looms large for families dealing with rare, genetic disorders

The Independent UK

Sarepta Catapults 30% After Hitting A 'Grand Slam' Approval In Muscular Dystrophy

Sarepta stock rocketed Friday after hitting a "grand slam" approval that expands the market for its Duchenne muscular dystrophy gene therapy more than tenfold, according to one estimate.

Investors Business Daily

Read news from The Economist, FT, and more,
with one subscription

Sarepta Jumps After Pfizer's Rival Gene Therapy Flops In Phase 3 Test

Sarepta stock jumped Thursday after Pfizer's rival gene therapy for Duchenne muscular dystrophy failed in final-phase testing.

Investors Business Daily

When there’s no commercial incentive to develop gene therapy – hospitals will try to fill the gap

Individually, rare diseases are rare, but there are so many rare diseases that over 400 million people are affected worldwide. Together, rare diseases aren’t so rare.

The Conversation

Children born deaf can hear in both ears in world-first gene therapy trial

Given as an infusion into the ear, the treatment works by replacing the faulty DNA which causes a type of inherited deafness known as DFNB9.

The Independent UK

Gene therapy trial gives deaf children hearing in both ears

Study participants born unable to hear could locate sound sources, recognise speech and dance to music after treatment

The Guardian - UK

Two deaf children can hear in both ears after world-first treatment

After the gene therapy, the children went from being profoundly deaf to having mild to moderate hearing loss

The Independent UK

Argentinian couple moves to US to allow their toddler to join gene therapy trial

The Lovatos relocated from Guatemala to Ohio for their son, who has the rare genetic disorder Canavan disease

The Guardian - US

Deaf baby can hear after 'mind-blowing' gene therapy treatment

Seven months after her treatment, the baby girl can now respond to her parents' voices without the aid of a cochlear implant.

LiveScience

Get all your
news in one place.

100’s of premium titles.
One news app.

The Guardian - UK

Great Ormond Street hoping to license gene therapy for ‘bubble baby’ syndrome

Hospital to take unprecedented step after drug firm pulled out despite successful trial of treatment

The Guardian - UK

UK toddler has hearing restored in world first gene therapy trial

Opal Sandy can hear almost perfectly after groundbreaking surgery that took just 16 minutes

The Hindu

Pfizer reports patient death in Duchenne gene therapy study

Pfizer's gene therapy trial for Duchenne muscular dystrophy resulted in a young patient's death from cardiac arrest

Investors Business Daily

Pfizer Wins FDA Approval For $3.5 Million Gene Therapy, Rivaling CSL, Uniqure

The FDA approved Pfizer's hemophilia gene therapy on Friday. But Pfizer stock only inched ahead on the approval early Friday.

Get all your
news in one place.

100’s of premium titles.
One news app.

Barchart

3 Standout Penny Stocks to Watch This April

Investing in penny stocks carries substantial risk, but also offers the potential for significant returns. These penny stocks, all with bullish analyst ratings, have considerable upside potential, according to Wall Street.

Top News

Gene Therapy Breakthroughs In The 1990S Revolutionized Medical Treatment.

Explore the pivotal era of gene therapy in the 1990s, from groundbreaking advancements to significant challenges, shaping modern regenerative medicine.

Investors Business Daily

How Sleeper Biotech Solid Biosciences, With A 687% Gain, Is Making A Comeback

Solid Biosciences is shrugging off several messy years in gene therapy development. The biotech stock has gotten a triple-digit boost.

Top News

Kyowa Kirin Gene Therapy: Most Expensive US Drug At .3M

Kyowa Kirin's .3 million gene therapy sparks debate on accessibility and pricing of innovative treatments in the US.

Top News

Kyowa Kirin's Gene Therapy: Most Expensive US Drug

Kyowa Kirin's .3 million gene therapy sparks debates on accessibility and affordability in healthcare.

Top News

Ensuring Quality Control In Cell And Gene Therapy Manufacturing

Learn about the importance of quality control in cell and gene therapy manufacturing for patient safety and market success.

The Hindu

German firm Miltenyi Biotec opens office, plans Cell and Gene Therapy CoE

Miltenyi Biotec launches operations in Hyderabad, investing in a Cell and Gene Therapy centre of excellence.

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.